WENDY L DIXON
CIK 1202283 · last filed 2025-05-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.87M
Companies
13
Total Filings
145
Lifetime Open-Market Net
-$7.76M
Filer Profile
Related Filers
INCYTE CORP — 45 joint filings, latest 2022-04-04
bluebird bio, Inc. — 10 joint filings, latest 2021-11-17
MICHAEL C ALFANO — 1 joint filings, latest 2010-05-12
ERIC BRANDT — 1 joint filings, latest 2010-05-12
PAULA H CHOLMONDELEY — 1 joint filings, latest 2010-05-12
MICHAEL J COLEMAN — 1 joint filings, latest 2010-05-12
WILLIAM F HECHT — 1 joint filings, latest 2010-05-12
LESLIE A JONES — 1 joint filings, latest 2010-05-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZVRA | Director | — | $12.40 | — | $0 | 3 | 2025-05-30 |
| BDTX | Director | 38,054 | $2.12 | $80.7K | $0 | 12 | 2024-04-03 |
| ARVN | Director | 9,121 | $9.39 | $85.6K | $0 | 4 | 2023-06-20 |
| ALKS | Director | 53,124 | $46.10 | $2.45M | -$1.05M | 21 | 2022-06-16 |
| IOVA | Director | — | $8.79 | — | $0 | 1 | 2022-06-14 |
| INCY | Director | 17,768 | $126.75 | $2.25M | -$6.71M | 43 | 2022-04-04 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 595 | $4.97 | $3.0K | $0 | 8 | 2021-11-17 |
| VYGR | Director | — | $3.51 | — | $0 | 5 | 2020-06-05 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | — | $12.58 | — | $0 | 2 | 2019-06-21 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | — | — | — | $0 | 4 | 2017-05-23 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | — | — | — | $0 | 6 | 2015-06-10 |
| Furiex Pharmaceuticals, Inc. (FURX) Delisted | Director | 7,160 | — | — | $0 | 7 | 2014-03-04 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | — | — | — | $0 | 3 | 2012-06-20 |
Recent Filings · Page 14 of 15
145 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-04-09 | — | Grant (A) | — | $0 | |
| 2009-03-20 | — | Grant (A) | — | $0 | |
| 2009-01-12 | — | Grant (A) | — | $0 | |
| 2008-12-18 | — | Grant (A) | — | $0 | |
| 2008-10-08 | — | Grant (A) | — | $0 | |
| 2008-07-30 | — | Grant (A) | — | $0 | |
| 2008-07-08 | — | Grant (A) | — | $0 | |
| 2008-06-26 | — | Grant (A) | — | $0 | |
| 2008-05-14 | — | Grant (A) | — | $0 | |
| 2008-04-09 | — | Grant (A) | — | $0 |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.